Ask VialBase
Research

Kisspeptin Administration in Post-COVID Neuroendocrine Dysfunction — VialBase Research

Trial Summary

Phase 1 trial investigating kisspeptin for post-COVID neuroendocrine dysfunction. Long COVID has been associated with hypothalamic-pituitary axis disruption, including hypogonadism, menstrual irregularity, and fatigue potentially driven by GnRH neuron dysfunction. Kisspeptin is the master upstream regulator of GnRH secretion and reproductive axis function.

Design

  • Type: Interventional, likely open-label or single-blind, proof-of-concept
  • Population: Adults with documented post-COVID syndrome and neuroendocrine symptoms (fatigue, hypogonadism, menstrual irregularity)
  • Arms: Kisspeptin infusion at physiological/pharmacological doses
  • Duration: Acute infusion study with follow-up hormonal assessments
  • Key measures: LH pulsatility pattern, FSH, testosterone/estradiol, cortisol, GH, prolactin, subjective symptom assessment

Key Outcomes

Trial is recruiting; no results available yet.

Significance for Peptide Research

This trial addresses an emerging clinical need (long COVID neuroendocrine effects) with a physiologically rational peptide approach. Kisspeptin’s role as the hypothalamic gatekeeper of reproduction makes it an ideal diagnostic and therapeutic tool for HPG axis dysfunction. If post-COVID neuroendocrine dysfunction is driven by hypothalamic kisspeptin neuron damage or dysfunction, exogenous kisspeptin could both diagnose the level of disruption and potentially restore normal pulsatile GnRH secretion. Connects to kisspeptin neuroendocrinology and long COVID neuroendocrine effects.

See Also